IASLC members understand state-of-the-art diagnosis and treatment for thoracic malignancies, many of which have been achieved in member research projects. However, it is difficult to put them all into clinical practice because of healthcare system regulations, financial issues, inappropriate bridging between research and treatment, and lack of specialized education, as well as other factors. The IASLC is the only international scientific society dedicated to the study of thoracic malignancies via a multidisciplinary approach, thus our strength is based on activities with multidisciplinary worldwide members like a united package from research to treatments. Similar to our previous achievements, the IASLC should lead in promotion of new standards, while the establishment of minimum standards is also essential. Such attempts by our global multidisciplinary organization can drive local regulatory bodies to raise standards to a higher level. In particular, in this COVID-19 pandemic era, the IASLC should be able to take a leading role to support healthcare professionals. I would like to contribute to developing an environment where effective cancer treatment can be delivered to patients as efficiently as possible, which would include pooling of knowledge presented in our journals, sharing experiences, and spreading information via SNS. Furthermore, the IASLC should support participation in registration studies, such as TERAVOLT, which are investigating risk factors for COVID-19-related deterioration of clinical conditions, serum biochemical data, cancer staging, treatment types, and other important issues related to safe and effective treatment of cancer patients.